What is the current stock price of Mauna Kea Technologies S.A. (MKEAF)?

As of the latest market data, Mauna Kea Technologies S.A. (MKEAF) is trading at $0.37. The stock has seen a loss of 0.00% today.

Does Mauna Kea Technologies S.A. (MKEAF) pay a dividend?

Based on current data, Mauna Kea Technologies S.A. does not have a confirmed active dividend policy.

What is the market cap of Mauna Kea Technologies S.A.?

The current market capitalization of Mauna Kea Technologies S.A. (MKEAF) is approximately unavailable.

MKEAF

Mauna Kea Technologies S.A.·Healthcare

0.37

0.000%(+0.00)

Close Price

Last Updated: — ET

52W L: $0.3752W H: $0.37

MKEAF NEWS

businesswire.com

Apr 22

Mauna Kea Technologies Reports FY 2025 Financial Results: Comprehensive Debt Restructuring and Reaccelerating Organic Growth Mark a Transformative 2025

PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today reported its financial results for the full year ended December 31, 2025, as approved by the Board of Directors on April 21st, 2026. "2025 was perhaps the most transformative year yet for Mauna Kea Technologies and what I believe is an inflection point in our financial and co.

businesswire.com

Apr 15

Mauna Kea Technologies Reports Strong Q1 2026 Core Sales Growth

PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today reported its revenue for the first quarter of 2026. Sacha Loiseau, Ph.D., Chairman and CEO of Mauna Kea Technologies, commented: "Our Q1 2026 performance confirms the robust growth trajectory initiated in the U.S. in 2025, which is now expanding internationally. This momentum.

Company Profile

Mauna Kea Technologies SA develops and markets medical devices in Europe, the Middle East, Africa, the United States, Latin America, and Asia. The company designs, develops, and markets tools to visualize and detect cell abnormalities in real time during standard gastrointestinal and pulmonary endoscopy procedures. Its flagship product is Cellvizio, a confocal miniprobe endomicroscopy system which provides physicians and researchers high-resolution images of tissues at the cellular level. The company was incorporated in 2000 and is headquartered in Paris, France.

Sector

Healthcare

Industry

Medical - Devices

Employees

IPO Date

2013-04-15

Beta

1.05

Websitewww.maunakeatech.com↗